Advertisement
Canada markets open in 7 hours 13 minutes

  • S&P/TSX

    21,740.20
    -159.79 (-0.73%)
     

  • S&P 500

    5,061.82
    -61.59 (-1.20%)
     

  • DOW

    37,735.11
    -248.13 (-0.65%)
     

  • CAD/USD

    0.7245
    -0.0008 (-0.11%)
     

  • CRUDE OIL

    85.90
    +0.49 (+0.57%)
     

  • Bitcoin CAD

    86,799.07
    -3,829.99 (-4.23%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • GOLD FUTURES

    2,403.90
    +20.90 (+0.88%)
     

  • RUSSELL 2000

    1,975.71
    -27.47 (-1.37%)
     

  • 10-Yr Bond

    4.6280
    0.0000 (0.00%)
     

  • NASDAQ futures

    17,855.75
    -20.50 (-0.11%)
     

  • VOLATILITY

    19.23
    +1.92 (+11.09%)
     

  • FTSE

    7,965.53
    -30.05 (-0.38%)
     

  • NIKKEI 225

    38,515.54
    -717.26 (-1.83%)
     

  • CAD/EUR

    0.6827
    +0.0003 (+0.04%)
     
MARKETS LIVE BLOG:

STOCKS SLIP WITH MIDEAST TENSIONS, EARNINGS IN PLAY

Oil pares losses as traders anticipate Israel's response to Iranian attack

Generation Bio to Present at the JMP Securities Life Sciences Conference

Generation Bio Co.
·1 min read
Generation Bio Co.
Generation Bio Co.

CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Matt Norkunas, M.D., chief financial officer, will present at the JMP Securities Life Sciences on Tuesday, May 16, 2023 at 1:00 p.m. EST in New York.

A live webcast of the presentation will be available on the investor section of the company’s website at investors.generationbio.com. A replay will be available there for 30 days following the event.

About Generation Bio
Generation Bio is innovating genetic medicines to provide durable, redosable treatments for people living with rare and prevalent diseases. The company’s non-viral genetic medicine platform incorporates a novel DNA construct called closed-ended DNA, or ceDNA; a unique cell-targeted lipid nanoparticle delivery system, or ctLNP; and a highly scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis, or RES, to produce ceDNA. This approach is designed to enable multi-year durability from a single dose, to deliver large genetic payloads, including multiple genes, to specific tissues and cell types, and to allow titration and redosing to adjust or extend expression levels in each patient. RES has the potential to expand Generation Bio’s manufacturing scale to hundreds of millions of doses to support its mission to extend the reach of genetic medicine to more people, living with more diseases, around the world.
For more information, please visit www.generationbio.com.

Investors and Media Contact
Maren Killackey
Generation Bio
mkillackey@generationbio.com
857-371-4638